Search

Your search keyword '"David J. Harrison"' showing total 616 results

Search Constraints

Start Over You searched for: Author "David J. Harrison" Remove constraint Author: "David J. Harrison"
616 results on '"David J. Harrison"'

Search Results

1. A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)

2. Adapting the design of the ongoing RAMPART trial in response to external evidence: An example for trials which take many years to run and report

3. Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine

4. Automated reporting of cervical biopsies using artificial intelligence

5. Deficiency of the paternally-expressed imprinted Peg3 gene in mice has sexually dimorphic consequences for offspring communication and social behaviour

6. Considerations for Gender‐Affirming Hormonal and Surgical Care Among Transgender and Gender Diverse Adolescents and Adults With Congenital Heart Disease

7. Magnifying Networks for Histopathological Images with Billions of Pixels

8. Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

9. Analysis of 983 civilian blast and ballistic casualties and the generation of a template of injury burden: An observational study

10. Transcription Factor NFE2L1 Decreases in Glomerulonephropathies after Podocyte Damage

11. Transition readiness in congenital heart disease: Are teens and young adults getting the recommended information?

12. Spatial immune profiling of the colorectal tumor microenvironment predicts good outcome in stage II patients

13. Whole-Slide Images and Patches of Clear Cell Renal Cell Carcinoma Tissue Sections Counterstained with Hoechst 33342, CD3, and CD8 Using Multiple Immunofluorescence

14. Spatial Analysis of NQO1 in Non-Small Cell Lung Cancer Shows Its Expression Is Independent of NRF1 and NRF2 in the Tumor Microenvironment

15. YAP Translocation Precedes Cytoskeletal Rearrangement in Podocyte Stress Response: A Podometric Investigation of Diabetic Nephropathy

16. Unified Behavioral Scoring for Preclinical Models

17. Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2)

18. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

19. The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro

20. The Effect of Tissue Preparation and Donor Age on Striatal Graft Morphology in the Mouse

21. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low‐Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients

22. Systems Analysis of Drug-Induced Receptor Tyrosine Kinase Reprogramming Following Targeted Mono- and Combination Anti-Cancer Therapy

23. Characterising the tumour morphological response to therapeutic intervention: an ex vivo model

25. An Analytical Approach Differentiates Between Individual and Collective Cancer Invasion

26. Biologic Cost per Effectively Treated Rheumatoid Arthritis Patient in a Large Managed Care Population: A Retrospective Cohort Study

27. The Use of Percutaneous Lumbar Fixation Screws for Bilateral Pedicle Fractures with an Associated Dislocation of a Lumbar Disc Prosthesis

28. Allosteric Modulation of Beta1 Integrin Function Induces Lung Tissue Repair

32. The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent

33. The immunopeptidome from a genomic perspective:Establishing the noncanonical landscape of MHC class I–associated peptides

34. Supplementary Table 3 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

35. Supplementary Table 2 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

36. Supplementary Table 5 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

37. Supplementary Table 1 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

38. Data from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

39. Supplementary figures from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

40. Supplementary legends from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

41. Supplementary notes from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

42. Supplementary Table 4 from The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides

43. Data from Automated Analysis of Lymphocytic Infiltration, Tumor Budding, and Their Spatial Relationship Improves Prognostic Accuracy in Colorectal Cancer

48. Data from Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer

50. Data from A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer

Catalog

Books, media, physical & digital resources